Skip to content

Evaluation of the safety and initial performance of the REPAIR Bone Putty in the treatment of patients with tibia fractures

A Randomized Controlled Clinical Study to Determine the Safety and Effectiveness of the REPAIR Bone Putty in Tibia Fractures

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201510001305535
Enrollment
30
Registered
2015-10-13
Start date
2012-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases Open tibia fractures

Interventions

REPAIR Bone Putty
Standard of care

Sponsors

Carmell Therapeutics Corp.
Lead Sponsor
3 Degree Clinical Research & Consulting
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients between the age of 18-75 inclusive; Patients with an acute open fracture of the tibial shaft secondary to trauma assessed by medical examination and radiograms indicated for open fracture reduction and mechanical fixation; Definitive Wound Closure (DWC) within 14 days of initial injury; In bilateral open tibia fractures, only one fracture meeting all inclusion/exclusion criteria will be treated ¿ should both fractures meet the criteria, the selected fracture will be randomly chosen; ¿ Subject is willing to be available for post operative follow-up examinations; Willingness and ability to understand, participate and comply with the study requirements; Able to give consent personally and to sign the Consent Form; Females of non-childbearing potential or who have a negative pregnancy test with 72 hours.

Exclusion criteria

Exclusion criteria: Type IIIc open fracture according to the Gustilo-Anderson classification; Tibial defects requiring bone grafting (e.g., large segmental defects); Duration from trauma to surgery longer than 14 days; Concomitant acute bone injuries and/or major skin or other injuries that in the opinion of the investigator would interfere with the tibial shaft fracture healing process; Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years; Subject is participating in another investigational trial that has not completed the primary study endpoint phase; Taking medication known to potentially interfere with bone/soft tissue healing (e.g., long term use of corticosteroids but not intended to exclude inhalation medication for asthma); Active infection at the operative site or a systemic infection; Any psychosocial disorders that could impact the follow up assessments or informed consent process.

Design outcomes

Primary

MeasureTime frame
Fracture healing;Safety

Secondary

MeasureTime frame
Wound assessment;Swelling;Tenderness;Neurovascular status;Infection;Weight Bearing

Countries

South Africa

Contacts

Public ContactHein Botha

3 Degree Clinical Research & Consulting

hein@3degreegroup.com021 531 7805

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026